Tandem Diabetes Care, Inc. (NASDAQ:TNDM) developer of medical devices for insulin-dependents, is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.1 per share.
Looking ahead, the full year loss are expected at $ 0.69 per share on the revenues of $ 462.16 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 450.00 million ~ $ 465.00 million
Click Here For More Historical Outlooks Of Tandem Diabetes Care, Inc.
Previous Quarter Performance
Tandem Diabetes Care, Inc. posted loss for the second quarter of $ 0.45 per share, from the revenue of $ 109.24 million. Street analysts expected Tandem Diabetes Care, Inc. to report loss of $ 0.24 per share on revenue of $ 87.15 million for the second quarter. The bottom line results missed street analysts by $ 0.21 or 87.5 percent, at the same time, top line results outshined analysts by $ 22.09 million or 25.35 percent.
Stock Performance
Shares of Tandem Diabetes Care, Inc. traded up $ 2.19 or 1.94 percent on Wednesday, reaching $ 115.26 with volume of 528.60 thousand shares. Tandem Diabetes Care, Inc. has traded high as $ 118.77 and has cracked $ 115.00 on the downward trend
The closing price of $ 115.26, representing a 158.80 % increase from the 52 week low of $ 43.69 and a 8.62 % decrease over the 52 week high of $ 123.74.
The company has a market capital of $ 7.02 billion and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Tandem Diabetes Care, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.tandemdiabetes.com
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The companys flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pumps software.
